CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies.  | The deal allows CSL to ...

When Expertise, Monitoring, Systems, and AI AlignBy Amir Malka, CEO, Bioforum The Data Masters | Trial oversight is shifting ...

Belgian biotech Agomab Therapeutics and eye-focused drug delivery company SpyGlass Pharma both headed to the Nasdaq this ...

Two dose-limiting toxicities have been recorded in uniQure’s trial evaluating an investigational AAV gene therapy designed to ...

Qiagen’s outgoing chief executive Thierry Bernard, M.D., told investors the company does not “comment on rumors” as takeover ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

Applied Medical has been awarded $382 million in damages from Medtronic after a U.S. District Court jury in California ...

Exxel Pharma is eyeing a listing on the NYSE American to fund human trials for a drug class that has previously struggled to ...

The Beacon trial enrolled 31 patients, randomizing them at a rate of 3:2:2 to receive a daily 45-mg oral dose of brepocitinib ...

Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. | Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as ...

Telehealth company Hims & Hers has added Grail’s blood cancer test Galleri to its offerings as the medtech has now sent off ...

Eikon announced itself in 2021 with former Merck & Co. exec Roger Perlmutter, M.D., Ph.D., at the helm and quickly ...